Background and Purpose: The effects of delayed thrombolysis with alteplase and neuroprotection with an excitatory amino acid receptor antagonist and their combination were tested in an embolic stroke model.
Neuroprotection by Excitatory Amino Acid
Antagonist Augments the Benefit of Thrombolysis in Embolic Stroke in Rats Tomas Sereghy, MD; Karsten Overgaard, MD; Gudrun Boysen, MD, DMSc Background and Purpose: The effects of delayed thrombolysis with alteplase and neuroprotection with an excitatory amino acid receptor antagonist and their combination were tested in an embolic stroke model.
Methods: In 61 rats the carotid artery territory was embolized with arterial-like fibrin-rich clots. Hemispheric cerebral blood flow before and after embolization was measured by intra-arterial '33Xe injection method. The animals were assigned to one of the following treatments: (1) vehicle-treated controls (n= 15); (2) dizocilpine 1 mg/kg IV 5 minutes after embolization (n= 16); (3) alteplase 20 mg/kg as an intravenous continuous infusion starting 2 hours after embolization (n=16); and (4) both agents (n= 14) . Carotid angiography displayed the site of occlusion of the cerebral arterial tree immediately after and 3 hours after embolization, and the clinical neurological score was assessed after the rats recovered from anesthesia and before the rats were killed. Brains were fixed after 2 days and evaluated neuropathologically; infarct volume affecting cortical and deep brain structures was measured separately.
Results: Both alteplase and dizocilpine reduced the total infarct volume (P=.05 and P=.04, respectively, Mann-Whitney tests). Dizocilpine reduced the incidence of cortical infarctions by 48% (P<.001, Fisher's test). Only the combined treatment significantly reduced deep brain infarctions (P=.03, Mann-Whitney test). The combined treatment also improved the clinical score by 83% compared with controls, by 75% compared with the group treated by dizocilpine alone, and by 50%o compared with the group treated by alteplase alone. Sixty-seven percent of thrombolytic-treated animals recanalized completely compared with 39%o of those given no thrombolytics (P=.05, Fisher 
Embolization and Cerebral Blood Flow Measurements
Just before and after embolization, cerebral blood flow (CBF) was measured using an intracarotid bolus injection of 0.15 to 0.20 mL saline containing 133Xe (5 to 10 mCi/mL, Amersham). As (4) combined treatment with both agents as described above (combined group).
After the second angiography, femoral and neck wounds were closed after ligation of vessels. The anesthesia was reverted with naloxone (Narcanti, Du Pont Pharmaceuticals) 0.1 mg IM. After recovering from anesthesia and just before being killed, the neurological deficit was assessed using the rating scale described by Bederson et al. 34 Rats were held by the tail 1 m above the floor. Normal rats extended both forelimbs toward the floor and were assigned grade 0. Rats with flexion of the forelimb contralateral to the injured hemisphere were graded 1, rats with reduced resistance to lateral push toward the paretic side were graded 2, and rats with spontaneous circling toward the paretic side were graded 3. Animals dying before being killed were assigned grade 3 on the second clinical evaluation.
Neuropathology
After 2 days' survival the animals were killed by formalin perfusion fixation and decapitated, and the heads were kept 24 hours embedded in 40% formalin solution. The brains were harvested, embedded in formalin for 3 weeks, and dehydrated. Horizontal serial sections of 4-,m slice thickness with a distance of 0.4 mm between each were stained with hematoxylin-eosin. Infarcted areas were characterized by nuclear pyknosis and cytoplasmic eosinophilia, swelling, and vacuolization of neurons. Infarcts affecting one of two following brain regions (Fig 2, top) , (1) Table  1 . No differences were found in any parameters measured at the time of embolization. At the end of the operating procedure, all treated groups had significantly lower pH, and both MK-801-treated groups had significantly lower MABP than controls.
The main results of the study are shown in Table 2 . The MK-801 group had an unintentional but significantly higher CBF reduction than the control group. No differences in initial angiographic occlusion values were found among any groups. The animals were sedated as they recovered from anesthesia; most showed flexion of the forelimb contralateral to the site of brain damage, asymmetrical posture, tilting of the head, and circling. All antagonism. They found an increased rCBF in the neocortex, caudate nucleus, entorhinal cortex, and corpus callosum of conscious rats40; glucose utilization was increased in the limbic structures, unaltered in the basal ganglia, and downregulated in the neocortex.4' Whether those changes in local CBF and metabolism can be caused by dopamine receptor blockade by MK-801,42 by NMDA antagonism alone (thereby allowing activation of local metabolism of adrenergic monoamines), or by some other interaction remains to be clarified. The NMDA receptor is blocked by acidosis,43-45 which could explain the lack of benefit when it is used in models of global severe ischemia.46 48 The objection has been raised that in some experiments documenting the benefit of NMDA antagonism the outcome could be attributed to hypothermia during and after the ischemic period rather than to its synaptic blockade.4649 In our experimental setting, the animals were maintained normothermic for at least 5 hours after embolization, after which period hypothermia might have occurred, but it would probably have been without pathophysiological importance. In our model, in which only small infarction (median, 20% of hemisphere volume in controls) develops and the brain surface is not exposed, the brain temperature corresponds well with the body temperature, so that rectal temperature monitoring is satisfactory. Hypotension in the two dizocilpine-treated groups is consistent with reports of others.22233032,35 This finding, as well as the acidosis that appeared in all our treated groups, could not improve the outcome.
There was a high variance of infarction volumes in the control group, and this variance further increased with every possibly beneficial intervention that was examined. This was caused partially by the variance of the location of the postembolic occlusion with our method of embolization and partially by the fact that the tendency to spontaneous recanalization occurs in most animals even without thrombolytic treatment ( Table 2 ). The variance of infarctions that developed makes the statistical analysis difficult and requires nonparametric statistical analysis, but it also resembles the clinical situation in the stroke population. To avoid further increases in the variance of this end point by having small infarctions or no infarctions caused by insufficient embolization in the control group, it was necessary to use the first angiogram in combination with CBF decrease as exclusion criteria in our experimental design, as reported in the "Materials and Methods" section.
There is consistent evidence that unlike the cortex, systemic NMDA blockade does not protect basal ganglia 
Editorial Comment
While basic scientists work to increase our understanding of the mechanisms of ischemic injury and to develop and refine valid models of ischemic stroke, clinical scientists are just beginning to evaluate some of the many potential therapeutic agents for stroke. As yet there are no accepted treatments to treat acute ischemic stroke. Agents being tested at the present time can be placed in three categories: neuroprotective therapy, thrombolytic therapy, and anticoagulant therapy. Testing a single agent for stroke treatment has proven to be a difficult and challenging task. Reports from laboratory research are already exploring the combination of two or more therapeutic agents. Such research can be extremely helpful in designing future clinical studies. Useful information from these studies includes information about the best time to administer each agent in relation to the other, drug interactions, and useful dosages. For instance, the neuroprotective agent dizocilpine was given after only 5 minutes of ischemia in the research reported here by Sereghy et al. The thrombolytic therapy, alteplase, was not given until 2 hours later. Could the dizocilpine be given any later and still have the same synergistic effect? Does early neuroprotective therapy increase the length of time that thrombolytic therapy can be effective? If an effective agent for stroke therapy ever is found, future clinical testing of agents may be made more difficult if control patients are receiving an active agent. This will increase the need for more data from the laboratory to help understand the relations between two or more therapeutic agents.
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